Clinical Course and Follow-Up o Type 1 Pseudohypoaldosteronism


Korkut S., Akın L., HATİPOĞLU N., Ozdemir A., Korkmaz L., Kendirci M., ...More

ERCIYES MEDICAL JOURNAL, vol.40, no.3, pp.113-119, 2018 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 3
  • Publication Date: 2018
  • Doi Number: 10.5152/etd.2018.0033
  • Journal Name: ERCIYES MEDICAL JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.113-119
  • Ondokuz Mayıs University Affiliated: No

Abstract

Objective: This study aimed to evaluate the management of primary pseudohypoaldosteronism type 1 (PHA1), which is a rare disease. Materials and Methods: We retrospectively reviewed the hospital records of patients who were followed up with a diagnosis of primary PHA1. Results: Of the eight patients diagnosed with primary PHA1, two had renal PHA1 and five had systemic PHA1. Five patients were initially administered steroids until a definite diagnosis was made. One patient was initially misdiagnosed with congenital adrenal hyperplasia due to "the high-dose hook effect". In patients with systemic PHA1, the highest salt requirement was 32-53 mEq/kg/day, which gradually decreased in all patients. Salt supplementation could not be stopped in patients with systemic PHA1 except one patient. Four of the eight patients died. Conclusion: After excluding the causes that may lead to secondary PHA in the initial evaluation of patients referred with a salt-depletion crisis, a differential diagnosis of congenital adrenal hyperplasia and PHA1 should be made. The hook effect and interference probabilities should be considered for evaluating hormone levels.